Literature DB >> 8784802

Clinical heterogeneity of seronegative myasthenia gravis.

A Evoli1, A P Batocchi, M Lo Monaco, S Servidei, L Padua, L Majolini, P Tonali.   

Abstract

We studied 38 patients affected by seronegative myasthenia gravis (SNMG) with age at the onset of the disease ranging from 6 to 66 yr. Clinical follow-up lasted at least 2 yr. Patients' lymphocyte cultures showed in no case anti-acetylcholine receptor antibody production; HLA associations did not differ significantly from those in seropositive MG. In most cases (33 out of 38) the disease differed from seropositive MG only in the low incidence of thymic pathology. In five cases the clinical picture was characterized by prevalent involvement of ocular and bulbar muscles and by a more stable course. These last group of patients did not respond satisfactorily to immunosuppressants, but they clearly improved with plasma-exchange. Mice injected with plasma IgG from four patients (two with typical clinical picture and two with prevalent oculobulbar involvement) showed a defect of neuromuscular transmission. In our experience, SNMG is a heterogeneous disease. A humorally mediated pathogenesis appears to be operating in both groups of patients we described.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784802     DOI: 10.1016/0960-8966(96)00009-0

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  10 in total

1.  Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.

Authors:  Rozen Le Panse; Géraldine Cizeron-Clairac; Jacky Bismuth; Sonia Berrih-Aknin
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 2.  Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Authors:  Michael H Rivner; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; Lin Mei
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

3.  Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.

Authors:  Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys
Journal:  J Neurol       Date:  2017-05-17       Impact factor: 4.849

4.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

5.  Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders?

Authors:  D Melis; F Balivo; R Della Casa; A Romano; R Taurisano; B Capaldo; G Riccardi; M R Monsurrò; G Parenti; G Andria
Journal:  J Inherit Metab Dis       Date:  2008-04-21       Impact factor: 4.982

6.  Induction of Anti-agrin Antibodies Causes Myasthenia Gravis in Mice.

Authors:  Min Yan; Ziyang Liu; Erkang Fei; Wenbing Chen; Xinsheng Lai; Bin Luo; Peng Chen; Hongyang Jing; Jin-Xiu Pan; Michael H Rivner; Wen-Cheng Xiong; Lin Mei
Journal:  Neuroscience       Date:  2018-01-13       Impact factor: 3.590

7.  ["Seronegative" myasthenia with antibodies against muscle-specific tyrosine-kinase].

Authors:  B Hain; F Hanisch; M Deschauer
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

8.  Double seronegative myasthenia gravis with antiphospholipid syndrome: a case report.

Authors:  Diana Dan; Pierre-Alexandre Bart; Jan Novy; Thierry Kuntzer; Carole Clair
Journal:  J Med Case Rep       Date:  2014-01-01

Review 9.  Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Lucia S Borges; David P Richman
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

Review 10.  Review Analysis on Thymectomy vs Conservative Medical Management in Myasthenia Gravis.

Authors:  Muhammad Humayoun Rashid; Hafiz Khawaja Muhammad Yasir; Muhammad Usman Piracha; Umer Salman; Hamza Yousaf
Journal:  Cureus       Date:  2020-03-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.